The promising metabolic benefits of FGF21 that contribute to the resolution of hepatic steatosis are supported by evidence from rodent models of NAFLD/MASLD and NASH/MASH, where FGF21 analogs have reduced hepatic steatosis. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.